New Insights into Semaglutide's Mechanism: Hunger Neurons Play a Key Role
Semaglutide, a widely used weight-loss medication found in drugs like Ozempic and Wegovy, has been shown to function in a more intricate manner than previously understood. Traditionally, the drug's weight-loss effects were attributed primarily to its ability to reduce appetite. However, new research published in the Proceedings of the National Academy of Sciences (PNAS) indicates that the drug's long-term efficacy may also depend on the activity of specific brain cells known as AgRP neurons, often referred to as 'hunger neurons.' These neurons are crucial for regulating the body's energy balance and mobilizing stored energy, such as fat.
In this study, led by Mateus d'Ávila from Yale University, researchers disrupted the function of AgRP neurons in female mice and subsequently treated them with semaglutide. Interestingly, while these mice continued to consume less food during the treatment, they experienced a diminished metabolic response, leading to weight regain within 15 days. In contrast, mice with intact AgRP neuron functionality were able to maintain their weight loss despite the drug's appetite-suppressing effects.
This finding raises important questions about the role of hunger neurons in weight management. The study suggests that the relationship between semaglutide and these neurons is not straightforward. While AgRP neurons are typically associated with hunger, their proper functioning appears to be essential for the sustained weight-lowering effects of semaglutide. The research team found that when the neurons were disrupted, the mice's ability to mobilize energy from fat was significantly impaired, which contributed to their weight regain.
Further experiments confirmed these results, demonstrating that the disruption of hunger neurons or interference with pathways that facilitate fat mobilization weakened semaglutide's effectiveness. Additionally, prolonged exposure to semaglutide altered the cellular activity and energy use within the AgRP neurons, indicating a complex interaction that warrants further investigation.
However, the study does have limitations. It was conducted solely on mice, and the effects observed were particularly pronounced in females, with male mice not exhibiting the same results under the tested conditions. The researchers emphasized that their findings should not be interpreted as guidance for human use of semaglutide or other GLP-1 drugs, as the study was preclinical and mechanistic in nature.
Previous research has shown that fast-acting GLP-1 drugs can inhibit AgRP neurons rapidly, correlating stronger inhibition with greater reductions in food intake. This new study does not negate those findings but rather adds a layer of complexity regarding the role of AgRP neurons during extended treatment periods. Understanding these mechanisms could be pivotal in explaining the varied responses individuals have to semaglutide and may inform the development of more effective weight-loss treatments in the future.




